|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
|
US8951966B2
(en)
|
2011-07-01 |
2015-02-10 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
|
|
CA2876689C
(en)
|
2012-06-13 |
2022-04-26 |
Incyte Corporation |
Substituted tricyclic compounds as fgfr inhibitors
|
|
NZ703495A
(en)
|
2012-07-11 |
2018-02-23 |
Blueprint Medicines Corp |
Inhibitors of the fibroblast growth factor receptor
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
EP3798228A1
(en)
|
2012-11-28 |
2021-03-31 |
NGM Biopharmaceuticals, Inc. |
Compositions and methods for treatment of metabolic disorders and diseases
|
|
US9290557B2
(en)
|
2012-11-28 |
2016-03-22 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants and fusions of FGF19 polypeptides
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
US9273107B2
(en)
|
2012-12-27 |
2016-03-01 |
Ngm Biopharmaceuticals, Inc. |
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
MX383664B
(es)
|
2012-12-27 |
2025-03-14 |
Ngm Biopharmaceuticals Inc |
Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
|
|
AR094812A1
(es)
|
2013-02-20 |
2015-08-26 |
Eisai R&D Man Co Ltd |
Derivado de piridina monocíclico como inhibidor del fgfr
|
|
TWI647220B
(zh)
|
2013-03-15 |
2019-01-11 |
美商西建卡爾有限責任公司 |
雜芳基化合物及其用途
|
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
|
MY181020A
(en)
|
2013-03-15 |
2020-12-16 |
Sanofi Sa |
Heteroaryl compounds and uses thereof
|
|
WO2014160521A1
(en)
|
2013-03-15 |
2014-10-02 |
Blueprint Medicines Corporation |
Piperazine derivatives and their use as kit modulators
|
|
PH12015502383B1
(en)
|
2013-04-19 |
2023-02-03 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
AU2014287209B2
(en)
*
|
2013-07-09 |
2019-01-24 |
Dana-Farber Cancer Institute, Inc. |
Kinase inhibitors for the treatment of disease
|
|
ES3069593T3
(en)
|
2013-08-23 |
2026-06-09 |
Neupharma Inc |
Quinazolin-8-yl derivatives for use in methods of treating melanoma, non-small cell lung cancer, thyroid cancer, ovarian cancer, or colon cancer
|
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Ｋｒａｓ ｇ１２ｃ之抑制劑
|
|
MX365614B
(es)
|
2013-10-17 |
2019-06-07 |
Blueprint Medicines Corp |
Composiciones utiles para tratar trastornos relacionados con kit.
|
|
SG11201602069WA
(en)
|
2013-10-18 |
2016-04-28 |
Eisai R&D Man Co Ltd |
Pyrimidine fgfr4 inhibitors
|
|
PT3395814T
(pt)
|
2013-10-25 |
2022-07-27 |
Blueprint Medicines Corp |
Inibidores do recetor do fator de crescimento de fibroblastos
|
|
CN105683188B
(zh)
|
2013-10-25 |
2018-02-09 |
诺华股份有限公司 |
作为fgfr4抑制剂的稠环二环吡啶基衍生物
|
|
NZ718962A
(en)
|
2013-10-28 |
2019-12-20 |
Ngm Biopharmaceuticals Inc |
Cancer models and associated methods
|
|
WO2015108992A1
(en)
|
2014-01-15 |
2015-07-23 |
Blueprint Medicines Corporation |
Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
|
|
US9828363B2
(en)
|
2014-01-20 |
2017-11-28 |
Cleave Biosciences, Inc. |
Fused pyrimidines as inhibitors of P97 complex
|
|
RS60593B1
(sr)
|
2014-01-24 |
2020-08-31 |
Ngm Biopharmaceuticals Inc |
Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
|
|
DK3102577T3
(en)
*
|
2014-02-07 |
2018-11-12 |
Principia Biopharma Inc |
QUINOLONDERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS
|
|
EP3114124A1
(en)
|
2014-03-03 |
2017-01-11 |
Principia Biopharma, Inc. |
BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS
|
|
MA38393B1
(fr)
|
2014-03-13 |
2018-11-30 |
Sanofi Sa |
Composés hétéroaryle et utilisations associées
|
|
US10398758B2
(en)
|
2014-05-28 |
2019-09-03 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
|
|
EP3155005A4
(en)
|
2014-06-16 |
2018-07-11 |
NGM Biopharmaceuticals, Inc. |
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
CN105017227B
(zh)
*
|
2014-07-08 |
2018-03-09 |
四川百利药业有限责任公司 |
N‑(1h‑吡唑‑5‑基)喹唑啉‑4‑胺类化合物
|
|
WO2016027781A1
(ja)
|
2014-08-18 |
2016-02-25 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
単環ピリジン誘導体の塩およびその結晶
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
ES2756748T3
(es)
|
2014-10-03 |
2020-04-27 |
Novartis Ag |
Uso de derivados de piridilo bicíclicos de anillo fusionado como inhibidores de fgfr4
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
SG11201702757YA
(en)
|
2014-10-23 |
2017-05-30 |
Ngm Biopharmaceuticals Inc |
Pharmaceutical compositions comprising peptide variants and methods of use thereof
|
|
US10434144B2
(en)
|
2014-11-07 |
2019-10-08 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
|
|
WO2016115412A1
(en)
*
|
2015-01-18 |
2016-07-21 |
Newave Pharmaceutical Llc |
Dual-warhead covalent inhibitors of fgfr-4
|
|
US10202365B2
(en)
|
2015-02-06 |
2019-02-12 |
Blueprint Medicines Corporation |
2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
|
|
EP3270694A4
(en)
*
|
2015-02-17 |
2018-09-05 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
CA2976790C
(en)
|
2015-02-20 |
2024-02-27 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
US9802917B2
(en)
|
2015-03-25 |
2017-10-31 |
Novartis Ag |
Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
|
|
EP3274344B1
(en)
|
2015-03-25 |
2019-04-24 |
Novartis Ag |
Formylated n-heterocyclic derivatives as fgfr4 inhibitors
|
|
CN114984013A
(zh)
|
2015-03-25 |
2022-09-02 |
国立癌症研究中心 |
胆管癌治疗剂
|
|
AU2016245864C1
(en)
|
2015-04-10 |
2021-09-09 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
CN107660200B
(zh)
|
2015-04-14 |
2022-01-11 |
卫材R&D管理有限公司 |
结晶fgfr4抑制剂化合物和其用途
|
|
ES2856880T3
(es)
|
2015-04-15 |
2021-09-28 |
Araxes Pharma Llc |
Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
|
|
US10538517B2
(en)
|
2015-05-22 |
2020-01-21 |
Principia Biopharma, Inc. |
Quinolone derivatives as FGFR inhibitors
|
|
EP3912979B1
(en)
|
2015-06-03 |
2026-03-25 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
CA2992586A1
(en)
|
2015-07-16 |
2017-01-19 |
Array Biopharma, Inc. |
Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
BR112018001190A2
(pt)
|
2015-07-24 |
2018-09-11 |
Blueprint Medicines Corp |
composições úteis para tratar distúrbios relacionados a kit e pdfgr
|
|
US10800843B2
(en)
|
2015-07-29 |
2020-10-13 |
Ngm Biopharmaceuticals, Inc. |
Beta klotho-binding proteins
|
|
EP3334735B1
(en)
*
|
2015-08-11 |
2025-08-13 |
Principia Biopharma Inc. |
Processes for preparing an fgfr inhibitor
|
|
WO2017035354A1
(en)
|
2015-08-26 |
2017-03-02 |
Blueprint Medicines Corporation |
Compounds and compositions useful for treating disorders related to ntrk
|
|
EP3356359B1
(en)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10975071B2
(en)
|
2015-09-28 |
2021-04-13 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
US10730867B2
(en)
|
2015-09-28 |
2020-08-04 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3365335B1
(en)
*
|
2015-10-23 |
2024-02-14 |
Array Biopharma, Inc. |
2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
|
|
EP3368039A1
(en)
|
2015-10-26 |
2018-09-05 |
The Regents of The University of Colorado, A Body Corporate |
Point mutations in trk inhibitor-resistant cancer and methods relating to the same
|
|
RS65069B1
(sr)
|
2015-11-02 |
2024-02-29 |
Blueprint Medicines Corp |
Inhibitori ret-a
|
|
JP6728352B2
(ja)
|
2015-11-09 |
2020-07-22 |
エヌジーエム バイオファーマシューティカルス，インコーポレーテッド |
胆汁酸に関係した障害の治療方法
|
|
KR102932353B1
(ko)
|
2015-11-16 |
2026-02-27 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
SG10201912607SA
(en)
|
2015-11-19 |
2020-02-27 |
Blueprint Medicines Corp |
Compounds and compositions useful for treating disorders related to ntrk
|
|
AU2016374441B2
(en)
|
2015-12-17 |
2021-10-21 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for breast cancer
|
|
CN105669566A
(zh)
*
|
2016-03-09 |
2016-06-15 |
华东师范大学 |
一种医药中间体n-芳基喹唑啉-2-胺化合物的制备方法
|
|
AR107912A1
(es)
|
2016-03-17 |
2018-06-28 |
Blueprint Medicines Corp |
Inhibidores de ret
|
|
UA125026C2
(uk)
|
2016-04-04 |
2021-12-29 |
Локсо Онколоджі, Інк. |
РІДКІ КОМПОЗИЦІЇ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)ПІРАЗОЛО[1,5-a]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ
|
|
UA125025C2
(uk)
|
2016-04-04 |
2021-12-29 |
Локсо Онколоджі, Інк. |
Способи лікування дитячих ракових захворювань
|
|
FI3442977T3
(fi)
|
2016-04-15 |
2023-09-26 |
Blueprint Medicines Corp |
Aktiviinireseptorin kaltaisen kinaasin estäjät
|
|
JP7372740B2
(ja)
|
2016-05-10 |
2023-11-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ
|
|
MX392604B
(es)
|
2016-05-18 |
2025-03-24 |
Array Biopharma Inc |
Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo.
|
|
KR20180002053A
(ko)
*
|
2016-06-28 |
2018-01-05 |
한미약품 주식회사 |
신규한 헤테로시클릭 유도체 화합물 및 이의 용도
|
|
WO2018004258A1
(ko)
*
|
2016-06-28 |
2018-01-04 |
한미약품 주식회사 |
신규한 헤테로시클릭 유도체 화합물 및 이의 용도
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
WO2018017983A1
(en)
|
2016-07-22 |
2018-01-25 |
Blueprint Medicines Corporation |
Compounds useful for treating disorders related to ret
|
|
US10035789B2
(en)
|
2016-07-27 |
2018-07-31 |
Blueprint Medicines Corporation |
Compounds useful for treating disorders related to RET
|
|
CN109843858B
(zh)
|
2016-08-15 |
2023-05-05 |
润新生物公司 |
某些化学实体、组合物及方法
|
|
US11370841B2
(en)
|
2016-08-26 |
2022-06-28 |
Ngm Biopharmaceuticals, Inc. |
Methods of treating fibroblast growth factor 19-mediated cancers and tumors
|
|
JP6751977B2
(ja)
*
|
2016-09-01 |
2020-09-09 |
南京薬捷安康生物科技有限公司 |
線維芽細胞増殖因子受容体の阻害剤及びそれらの使用
|
|
CN110022900A
(zh)
*
|
2016-09-08 |
2019-07-16 |
蓝图药品公司 |
成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合
|
|
WO2018055503A1
(en)
|
2016-09-20 |
2018-03-29 |
Novartis Ag |
Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
|
|
JP2019529484A
(ja)
|
2016-09-29 |
2019-10-17 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤
|
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
|
TWI752098B
(zh)
|
2016-10-10 |
2022-01-11 |
美商亞雷生物製藥股份有限公司 |
作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
|
|
TWI704148B
(zh)
|
2016-10-10 |
2020-09-11 |
美商亞雷生物製藥股份有限公司 |
作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
|
|
WO2018072707A1
(zh)
*
|
2016-10-18 |
2018-04-26 |
保诺科技（北京）有限公司 |
芳香族醚类衍生物、其制备方法及其在医药上的应用
|
|
JOP20190092A1
(ar)
|
2016-10-26 |
2019-04-25 |
Array Biopharma Inc |
عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
|
|
JP7394623B2
(ja)
|
2016-11-02 |
2023-12-08 |
ノバルティス アーゲー |
Ｆｇｆｒ４インヒビターおよび胆汁酸捕捉薬の組合せ
|
|
MX389403B
(es)
*
|
2016-11-17 |
2025-03-20 |
Guangdong Zhongsheng Pharmaceutical Co Ltd |
Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo
|
|
KR101812266B1
(ko)
|
2016-11-25 |
2017-12-27 |
한국과학기술연구원 |
4-((2-아크릴아미도페닐)아미노)티에노[3,2-d]피리미딘-7-카복스아미드 유도체 및 그의 약학적 활용
|
|
RU2747260C2
(ru)
*
|
2016-12-19 |
2021-04-29 |
Аббиско Тхерапеутицс Цо., Лтд. |
Ингибитор рфрф4, способ его получения и его фармацевтическое применение
|
|
CN108239069B
(zh)
*
|
2016-12-26 |
2021-01-05 |
南京药捷安康生物科技有限公司 |
一种用于成纤维细胞生长因子受体的抑制剂及其用途
|
|
CN108264511B
(zh)
*
|
2017-01-03 |
2021-04-13 |
浙江海正药业股份有限公司 |
杂环类衍生物及其制备方法和其在医药上的用途
|
|
JP6888101B2
(ja)
|
2017-01-18 |
2021-06-16 |
アレイ バイオファーマ インコーポレイテッド |
ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
|
|
WO2018136663A1
(en)
|
2017-01-18 |
2018-07-26 |
Array Biopharma, Inc. |
Ret inhibitors
|
|
EP3573971A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
JP7327802B2
(ja)
|
2017-01-26 |
2023-08-16 |
アラクセス ファーマ エルエルシー |
縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
|
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
|
CN108503593B
(zh)
*
|
2017-02-28 |
2021-04-27 |
暨南大学 |
2-氨基嘧啶类化合物及其应用
|
|
JOP20190213A1
(ar)
|
2017-03-16 |
2019-09-16 |
Array Biopharma Inc |
مركبات حلقية ضخمة كمثبطات لكيناز ros1
|
|
WO2018183712A1
(en)
|
2017-03-31 |
2018-10-04 |
Blueprint Medicines Corporation |
Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
|
|
CN110869358A
(zh)
|
2017-05-25 |
2020-03-06 |
亚瑞克西斯制药公司 |
Kras的共价抑制剂
|
|
TW201906832A
(zh)
|
2017-05-25 |
2019-02-16 |
美商亞瑞克西斯製藥公司 |
用於癌症治療之化合物及其使用方法
|
|
WO2018218069A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
EP3444275A1
(en)
|
2017-08-16 |
2019-02-20 |
Exiris S.r.l. |
Monoclonal antibody anti-fgfr4
|
|
CN110997637B
(zh)
*
|
2017-09-05 |
2022-09-27 |
保仕健生物科技(上海)有限公司 |
芳香类衍生物、其制备方法及其在医药上的应用
|
|
TWI876442B
(zh)
|
2017-10-10 |
2025-03-11 |
美商絡速藥業公司 |
6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
|
|
TWI791053B
(zh)
|
2017-10-10 |
2023-02-01 |
美商亞雷生物製藥股份有限公司 |
6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
|
|
KR102717072B1
(ko)
|
2017-10-18 |
2024-10-15 |
인사이트 코포레이션 |
Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체
|
|
KR20190043437A
(ko)
|
2017-10-18 |
2019-04-26 |
씨제이헬스케어 주식회사 |
단백질 키나제 억제제로서의 헤테로고리 화합물
|
|
EP3697786B1
(en)
|
2017-10-18 |
2022-08-31 |
Blueprint Medicines Corporation |
Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
|
|
CN109721600B
(zh)
*
|
2017-10-30 |
2021-04-27 |
上海凌达生物医药有限公司 |
一类含氮稠环化合物及其制备方法和用途
|
|
EP3740491A1
(en)
|
2018-01-18 |
2020-11-25 |
Array Biopharma, Inc. |
Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
|
|
EP3740486A1
(en)
|
2018-01-18 |
2020-11-25 |
Array Biopharma, Inc. |
Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
|
|
CN111630054B
(zh)
|
2018-01-18 |
2023-05-09 |
奥瑞生物药品公司 |
作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
|
|
CN111683928B
(zh)
*
|
2018-02-08 |
2021-12-10 |
漳州片仔癀药业股份有限公司 |
作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物
|
|
BR112020017922A2
(pt)
|
2018-03-28 |
2020-12-22 |
Eisai R&D Management Co., Ltd. |
Agente terapêutico para carcinoma hepatocelular
|
|
SG11202009681YA
(en)
|
2018-04-03 |
2020-10-29 |
Blueprint Medicines Corp |
Ret inhibitor for use in treating cancer having a ret alteration
|
|
CN110386921A
(zh)
*
|
2018-04-23 |
2019-10-29 |
南京药捷安康生物科技有限公司 |
成纤维细胞生长因子受体抑制剂化合物
|
|
RS66310B1
(sr)
|
2018-05-04 |
2025-01-31 |
Incyte Corp |
Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
|
|
KR102956194B1
(ko)
|
2018-05-04 |
2026-04-23 |
인사이트 코포레이션 |
Fgfr 억제제의 염
|
|
WO2019223766A1
(zh)
*
|
2018-05-25 |
2019-11-28 |
上海和誉生物医药科技有限公司 |
一种fgfr抑制剂、其制备方法和在药学上的应用
|
|
CN110577524B
(zh)
*
|
2018-06-07 |
2022-01-28 |
北京大学深圳研究生院 |
一种激酶选择性抑制剂
|
|
WO2019242689A1
(zh)
*
|
2018-06-22 |
2019-12-26 |
北京赛特明强医药科技有限公司 |
一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
|
|
CA3108065C
(en)
|
2018-07-31 |
2025-10-07 |
Loxo Oncology, Inc. |
SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
|
|
BR112021001709A2
(pt)
|
2018-08-01 |
2021-05-04 |
Araxes Pharma Llc |
compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
|
|
CR20250050A
(es)
|
2018-09-05 |
2025-03-19 |
Incyte Corp |
Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
|
|
ES2922314T3
(es)
|
2018-09-10 |
2022-09-13 |
Array Biopharma Inc |
Compuestos heterocíclicos condensados como inhibidores de cinasa RET
|
|
WO2020052349A1
(zh)
*
|
2018-09-14 |
2020-03-19 |
上海和誉生物医药科技有限公司 |
Fgfr抑制剂、其制备方法和应用
|
|
CN110950867A
(zh)
*
|
2018-09-27 |
2020-04-03 |
首药控股(北京)有限公司 |
一种fgfr4激酶抑制剂及其制备方法和用途
|
|
CN111138459B
(zh)
*
|
2018-11-06 |
2022-10-18 |
南京圣和药业股份有限公司 |
Fgfr4抑制剂的光学异构体及其应用
|
|
KR102195348B1
(ko)
|
2018-11-15 |
2020-12-24 |
에이치케이이노엔 주식회사 |
단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
|
|
WO2020119606A1
(en)
*
|
2018-12-10 |
2020-06-18 |
Guangdong Newopp Biopharmaceuticals Co., Ltd. |
Heterocyclic compounds as inhibitors of fibroblast growth factor receptor
|
|
WO2020131627A1
(en)
|
2018-12-19 |
2020-06-25 |
Array Biopharma Inc. |
Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
|
|
US12351571B2
(en)
|
2018-12-19 |
2025-07-08 |
Array Biopharma Inc. |
Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases
|
|
WO2020177067A1
(en)
*
|
2019-03-05 |
2020-09-10 |
Bioardis Llc |
Aromatic derivatives, preparation methods, and medical uses thereof
|
|
EP3936509B1
(en)
*
|
2019-03-08 |
2024-07-31 |
Shouyao Holdings (Beijing) Co., Ltd. |
Fgfr4 kinase inhibitor, preparation method therefor and use thereof
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
HUE064283T2
(hu)
|
2019-04-12 |
2024-02-28 |
Blueprint Medicines Corp |
Az (S)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1H-pirazol-4-il)pirrolo[2,1-f][1,2,4]triazin-4-il) piperazinil)-pirimidin-5-il)etán-1-amin kristályos formái és elõállítási eljárásai
|
|
CN110317176A
(zh)
*
|
2019-07-04 |
2019-10-11 |
沈阳药科大学 |
2-氨基嘧啶类化合物及其用途
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US12378241B2
(en)
|
2019-07-26 |
2025-08-05 |
Cgenetech (Suzhou,China) Co., Ltd. |
Pyridine derivative as FGFR and VEGFR dual inhibitors
|
|
WO2021023195A1
(zh)
*
|
2019-08-08 |
2021-02-11 |
漳州片仔癀药业股份有限公司 |
吡嗪-2（1h）-酮类化合物的d晶型及其制备方法
|
|
WO2021023193A1
(zh)
*
|
2019-08-08 |
2021-02-11 |
漳州片仔癀药业股份有限公司 |
吡嗪-2(1h)-酮类化合物的制备方法
|
|
WO2021023192A1
(zh)
*
|
2019-08-08 |
2021-02-11 |
漳州片仔癀药业股份有限公司 |
吡嗪-2(1h)-酮类化合物的a晶型和b晶型及其制备方法
|
|
US12122767B2
(en)
|
2019-10-01 |
2024-10-22 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
GEP20247679B
(en)
|
2019-10-14 |
2024-10-10 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
CN112759593A
(zh)
|
2019-11-01 |
2021-05-07 |
北京伯汇生物技术有限公司 |
桥环并醛基吡啶衍生物及其应用
|
|
WO2021113479A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
MX2022006691A
(es)
|
2019-12-04 |
2022-09-19 |
Incyte Corp |
Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
|
|
US20230101747A1
(en)
|
2019-12-06 |
2023-03-30 |
Schrödinger, Inc. |
Cyclic compounds and methods of using same
|
|
AU2020414132B2
(en)
|
2019-12-23 |
2024-02-15 |
Beijing Scitech-Mq Pharmaceuticals Limited |
Cyano-substituted pyridine and cyano-substituted pyrimidine compound and preparation method therefor and application thereof
|
|
IL294214B2
(en)
|
2019-12-27 |
2026-04-01 |
Schrodinger Inc |
Cyclic compounds and methods of using same
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021243192A1
(en)
|
2020-05-29 |
2021-12-02 |
Blueprint Medicines Corporation |
Solid forms of pralsetinib
|
|
CR20220666A
(es)
|
2020-05-29 |
2023-05-05 |
Blueprint Medicines Corp |
Composiciones farmacéuticas de pralsetinib
|
|
EP4161657A1
(en)
*
|
2020-06-05 |
2023-04-12 |
Kinnate Biopharma Inc. |
Inhibitors of fibroblast growth factor receptor kinases
|
|
CN116490507A
(zh)
|
2020-09-10 |
2023-07-25 |
薛定谔公司 |
用于治疗癌症的杂环包缩合cdc7激酶抑制剂
|
|
CN112851587A
(zh)
*
|
2021-01-21 |
2021-05-28 |
药雅科技(上海)有限公司 |
一种用于治疗癌症的炔类杂环化合物及其制备方法与用途
|
|
EP4284804A1
(en)
|
2021-01-26 |
2023-12-06 |
Schrödinger, Inc. |
Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
|
|
WO2022161408A1
(zh)
*
|
2021-01-26 |
2022-08-04 |
南京明德新药研发有限公司 |
甲基吡唑取代的吡啶并咪唑类化合物的晶型及其制备方法
|
|
CN114853740B
(zh)
*
|
2021-02-03 |
2023-08-01 |
药雅科技(上海)有限公司 |
炔类嘧啶化合物作为fgfr抑制剂的制备方法和用途
|
|
AR125588A1
(es)
*
|
2021-03-04 |
2023-08-02 |
Lilly Co Eli |
Compuestos inhibidores de fgfr3
|
|
WO2022194160A1
(zh)
*
|
2021-03-16 |
2022-09-22 |
上海启晟合研医药科技有限公司 |
非索替尼固体形式及其制备方法
|
|
TW202300150A
(zh)
|
2021-03-18 |
2023-01-01 |
美商薛定諤公司 |
環狀化合物及其使用方法
|
|
AU2021436754B2
(en)
*
|
2021-03-26 |
2024-11-07 |
Apeloa Pharmaceutical Co., Ltd. |
Bicyclic heterocyclic fgfr4 inhibitor, pharmaceutical composition and preparation comprising same, and application thereof
|
|
EP4323405A1
(en)
|
2021-04-12 |
2024-02-21 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
CA3220274A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
TW202313610A
(zh)
|
2021-06-09 |
2023-04-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之三環雜環
|
|
CN113912602B
(zh)
*
|
2021-10-14 |
2023-05-05 |
温州医科大学 |
一种2-氧代-1,2-二氢-1,6-萘啶-7-基类化合物及其制备方法和用途
|
|
WO2024242495A1
(ko)
*
|
2023-05-25 |
2024-11-28 |
주식회사 매직불릿테라퓨틱스 |
단백질 키나아제 억제용 신규 화합물 및 이를 포함하는 약학조성물
|
|
TWI896159B
(zh)
*
|
2023-06-09 |
2025-09-01 |
大陸商上海和譽生物醫藥科技有限公司 |
一種fgfr4抑制劑組合物、其製備方法和在藥學上的應用
|
|
EP4509142A1
(en)
|
2023-08-16 |
2025-02-19 |
Ona Therapeutics S.L. |
Fgfr4 as target in cancer treatment
|
|
CN122003418A
(zh)
|
2023-09-11 |
2026-05-08 |
薛定谔公司 |
作为malt1抑制剂的环戊并[e]吡唑并[1,5-a]嘧啶衍生物
|